Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | SVP, Chief Development Officer | June 07, 2020 | June 08, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protalix BioTherapeutics, Inc.
Report date June 07, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2030-06-07 | Direct | 196,995 |
Reported balance
After 2020-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-07 · Grant · Acquired 196,995 · Balance 196,995 F1: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2: Does not include (i) options to purchase 25,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025; and (ii) options to purchase 70,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
F2: Does not include (i) options to purchase 25,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025; and (ii) options to purchase 70,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2020 Filed Jun 8, 2020 21:07 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 196,995 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001104659-20-070906 · tm2022027d1_4.xml · derivative · entry 1 Almon Einat Brill · CIK 0001385116 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,995 Underlying: Common Stock · 196,995 shares Expires 2030-06-07 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 25,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025; and (ii) options to purchase 70,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2025. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 20:31 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001144204-18-049522 · tv502883_4.xml · derivative · entry 1 Almon Einat Brill · CIK 0001385116 · SVP, Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2028-09-13 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.